GlassScriptPhysician profile
Mark E Clarke
NPI 1790850584
$37,335.51
in general payments reported to CMS, 2019-2025
62 companies · $7,652 in 2025
The $7,652 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,676 · 2022: $6,551 · 2023: $8,090 · 2024: $7,367 · 2025: $7,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,108.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,885.63 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,476.60 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $2,269.29 | 2021-2025 | |
| Glaxosmithkline, LLC. | $2,204.30 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $2,104.52 | 2022-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $1,903.40 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $1,887.46 | 2021-2024 | Xarelto |
| Vanda Pharmaceuticals INC. | $1,809.38 | 2021-2025 | Hetlioz, Fanapt |
| Sanofi-Aventis U.S. LLC | $1,496.91 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,425.41 | 2021-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Pfizer INC. | $1,409.61 | 2021-2025 | |
| Lilly USA, LLC | $1,389.50 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $1,334.55 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,196.93 | 2021-2023 | Trintellix |
| Antares Pharma, INC. | $822.86 | 2021-2025 | Xyosted, Tlando, Nocdurna |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $821.77 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $746.81 | 2021 | |
| Axsome Therapeutics, INC. | $692.36 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $445.34 | 2022-2025 | |
| Tolmar, INC. | $442.29 | 2023-2025 | Jatenzo |
| Corium, LLC | $438.57 | 2022-2024 | Azstarys |
| Phathom Pharmaceuticals, INC. | $426.61 | 2023-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $345.56 | 2023-2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $344.97 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $338.08 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Otsuka America Pharmaceutical, INC. | $331.81 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $321.68 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $310.25 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $281.57 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $261.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $245.95 | 2022-2025 | Eliquis, Camzyos |
| Mylan Specialty L.P. | $235.48 | 2021-2024 | Yupelri, Yupelri |
| Idorsia Pharmaceuticals US INC | $205.02 | 2022-2024 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $189.18 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $161.30 | 2021-2024 | |
| Verona Pharma, INC. | $160.48 | 2025 | Ohtuvayre |
| Currax Pharmaceuticals LLC | $157.62 | 2021-2024 | Contrave |
| Nevro Corp. | $153.73 | 2021 | |
| Ardelyx, INC. | $143.44 | 2024-2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $140.16 | 2021 | |
| Abiomed | $133.03 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.76 | 2022 | |
| Eisai INC. | $116.43 | 2021 | |
| Cochlear Americas | $102.42 | 2024 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Acerus Pharmaceuticals Corporation | $102.09 | 2021-2022 | |
| Lucid Diagnostics INC. | $86.16 | 2024 | |
| Merck Sharp & Dohme LLC | $80.60 | 2023 | Verquvo, Belsomra, Steglatro |
| Bausch Health US, LLC | $74.15 | 2024-2025 | Wellbutrin, Aplenzin |
| Amarin Pharma, INC. | $73.06 | 2021-2022 | |
| Corcept Therapeutics | $70.97 | 2024 | Korlym |
| Verity Pharmaceuticals INC. | $64.73 | 2024-2025 | Tlando |
| Ibsa Pharma INC. | $56.50 | 2023 | Tirosint, Licart |
| Astellas Pharma US INC | $50.48 | 2025 | Veozah |
| Myriad Women'S Health, INC. | $43.60 | 2023 | Myrisk |
| Dexcom, INC. | $35.36 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Scientific Affairs, LLC | $30.59 | 2022 | |
| Sumitomo Pharma America, INC. | $28.73 | 2024-2025 | Gemtesa |
| Almatica Pharma LLC | $28.43 | 2021-2022 | |
| Halozyme INC | $24.51 | 2023 | |
| Horizon Therapeutics Plc | $22.14 | 2021 | |
| Redhill Biopharma INC. | $19.34 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.26 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.